Oligonucleotide & Peptide Therapeutics
-低聚核苷酸與胜肽療法波士頓年會-
日期:2018年3月26-28日
地點:美國馬薩諸塞州劍橋,Boston Marriott Cambridge

已知的疾病標的中能夠成功滿足治療需求的寥寥無幾。我們對疾病生物學的了解持續超過我們發展治療藥物的能力,找出一個新方法盡可能破解這個「無法藥物化」的標的群體之需求已經迫在眉梢。低聚核苷酸與胜肽療法作為面對此挑戰的新興關鍵模式,不但可以生產高度專一性、多樣性的安全藥物,更比傳統小分子藥物及生物製劑能夠對應更廣泛的標的。

在美國麻州由Cambridge Healthtech Institute (CHI)所主辦的第3屆Oligonucleotide and Peptide Therapeutics (OPT) Boston已在業界建立鞏固地位,將聚集致力於低聚核苷酸與胜肽療法開發的主要企業與技術供應商代表,針對次世代藥物的發現、開發、運輸等各領域的進步進行討論。本活動將為期三天,網羅了創藥、運輸、早期階段臨床研究等主題的兩大主題研討會之外,另將舉行聚焦於罕見疾病治療應用的主題論壇。

 
 

 
 

2017 Features

200+ Participants • 84% from Leading Biotech & Pharma Companies • 43% growth in 2017

"No events go without a hitch, but your crack team met all the obstacle[s] head on, to our complete satisfaction. We've already signed up for the next event."
- Rick N., President, Oligo Factory

"It was my first time attending the show, and I was very impressed with the variety of speakers and content."
- Chris M., Ph.D. , Director, Business Development, Bachem Americas, Inc.

"This three-day meeting combines frontier works from both academic and industry which truly illustrated the current status of oligonucleotides therapeutics."
- Patrick L., Ph.D., President & CEO, Sirnaomics, Inc.